Clinical Trials
296 trialsOrigAMI-1
Janssen Research & Development, LLC
ARC-25
Arcus Biosciences, Inc.
OrigAMI-2
Janssen Research & Development, LLC
OrigAMI-3
Janssen Research & Development, LLC
MOUNTAINEER-03
Seagen Inc.
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Genmab
EDGE-Gastric
Arcus Biosciences, Inc.
STAR-221
Arcus Biosciences, Inc.
RASolute 302
Revolution Medicines, Inc.
AndroMETa-CRC
AbbVie
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Astellas Pharma Inc
RASolute 305
Revolution Medicines, Inc.
A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors
Crossignal Therapeutics, Inc.
KANDLELIT-012
Merck Sharp & Dohme LLC
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
Astellas Pharma Inc
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
BOLSTER
Lisata Therapeutics, Inc.
MK-3475-06C
Merck Sharp & Dohme LLC
eVOLVE-02
AstraZeneca
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
Sichuan Baili Pharmaceutical Co., Ltd.
MK-3475-C66
Merck Sharp & Dohme LLC
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
EMD Serono
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01)
Sichuan Baili Pharmaceutical Co., Ltd.
HERIZON-GEA-01
Jazz Pharmaceuticals
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Bold Therapeutics, Inc.
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
Ono Pharmaceutical Co., Ltd.
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
AstraZeneca
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
AstraZeneca
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
I-Mab Biopharma US Limited
KEYNOTE 975
Merck Sharp & Dohme LLC
DG-03
AstraZeneca
A Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
AstraZeneca
EGRET
AstraZeneca
CANTOR
AstraZeneca
A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
BeOne Medicines
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Pfizer
HARMONi-GI3
Summit Therapeutics
Spotlight
Astellas Pharma Inc
NAUTICALCRC
Pierre Fabre Medicament
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
Sichuan Baili Pharmaceutical Co., Ltd.
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Tyligand Pharmaceuticals (Suzhou) Limited
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Akeso
A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
R-Pharm
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
Hoffmann-La Roche
NAPOLI 3
Ipsen
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Seagen Inc.
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer